Diagnostic Performance of cfDNA ‐Based Liquid Biopsy for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis
Cancer Science · 20.10.2026
DOI: 10.1111/cas.70551 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 20.10.2026. Verfasst von Jiwei Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Meihe Health Research Institute, The First Hospital of Jilin University, Changchun, China. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Science and Technology of Jilin Province, Jilin Provincial Science and Technology Development Plan Project, National Natural Science Foundation of China, Department of Science and Technology of Jilin Province.
Abstract (Originalsprache)
Conventional surveillance tools for hepatocellular carcinoma (HCC) have limited sensitivity. Circulating cell‐free DNA (cfDNA)‐based liquid biopsy is a promising minimally invasive approach; however, its overall diagnostic performance remains unclear. This meta‐analysis aimed to comprehensively evaluate the diagnostic accuracy of cfDNA‐based liquid biopsy in HCC. Following PRISMA‐DTA guidelines, we searched PubMed, EMBASE, and Web of Science until July 2026. Diagnostic accuracy data were pooled using bivariate random‐effects models. Methodological quality was assessed using QUADAS‐2 and NOS. A total of 29 studies (4250 HCC patients, 7982 controls) were included. Pooled sensitivity and specificity of cfDNA‐based testing were 0.82 (95% CI: 0.76–0.86) and 0.91 (95% CI: 0.88–0.93). The area under the summary receiver operating characteristic curve (AUC) was 0.93 (95% CI: 0.91–0.96). Subgroup analyses showed higher sensitivity in advanced HCC 0.91 (95% CI: 0.85–0.95) than early HCC 0.77 (95% CI: 0.71–0.83). Methylation profiling yielded relatively higher sensitivity 0.84 (95% CI: 0.77–0.89), whereas fragmentomics showed relatively favorable specificity 0.93 (95% CI: 0.88–0.96). Combining cfDNA‐based testing with alpha‐fetoprotein (AFP) significantly improved sensitivity compared with cfDNA alone (0.78 vs. 0.65). No significant publication bias was detected ( p = 0.83). cfDNA‐based liquid biopsy achieves high diagnostic accuracy for HCC. As exploratory observations, methylation‐based assays with relatively higher sensitivity may have potential value for screening high‐risk populations, while fragmentomics‐based assays with relatively favorable specificity may aid differential diagnosis. Combining cfDNA‐based liquid biopsy with AFP further improves diagnostic performance, supporting cfDNA as a promising noninvasive tool for HCC detection. Trial Registration: This systematic review was registered on PROSPERO: CRD420261293877 ( https://www.crd.york.ac.uk/PROSPERO/ )
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Meihe Health Research Institute, The First Hospital of Jilin University, Changchun, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
ORCID-Profile: Jiwei Liu, Jing Jiang
Förderung
- Department of Science and Technology of Jilin Province, Jilin Provincial Science and Technology Development Plan Project
- National Natural Science Foundation of China
- Department of Science and Technology of Jilin Province
Zitieren
APA
Liu, J., Zhang, Y., Yang, S., Wu, Y., & Jiang, J. (2026). Diagnostic Performance of cfDNA ‐Based Liquid Biopsy for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. Cancer Science. https://doi.org/10.1111/cas.70551
Vancouver
Liu J, Zhang Y, Yang S, Wu Y, Jiang J. Diagnostic Performance of cfDNA ‐Based Liquid Biopsy for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. Cancer Science. 2026. doi:10.1111/cas.70551
BibTeX
@article{Liu2026,
author = {Liu, Jiwei and Zhang, Yangyu and Yang, Shuo and Wu, Yanhua and Jiang, Jing},
title = {Diagnostic Performance of cfDNA ‐Based Liquid Biopsy for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70551}
}
EUVIMED